Lilly, Sigilon Launch Up-to-$473M+ Type 1 Diabetes Partnership

Eli Lilly will partner with Sigilon Therapeutics to develop encapsulated cell therapies as treatments for type 1 diabetes, through a collaboration that could generate up to $473 million-plus for the year-old startup, the companies said today.Based in Cambridge, MA, privately held Sigilon focuses on discovering and developing "living therapeutics" through its Afibromer™ technology product platform. Afibromer stands for “afibrotic polymers which do not trigger a fibrotic response.&rdqu